Literature DB >> 16913702

Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.

Muthukaman Nagarajan1, Andrew Morrell, Smitha Antony, Glenda Kohlhagen, Keli Agama, Yves Pommier, Patricia A Ragazzon, Nichola C Garbett, Jonathan B Chaires, Melinda Hollingshead, Mark Cushman.   

Abstract

The indenoisoquinolines represent a class of non-camptothecin topoisomerase I (Top1) inhibitors that exert cytotoxicity by trapping the covalent complex formed between DNA and Top1 during relaxation of DNA supercoils. As an ongoing evaluation of Top1 inhibition and anticancer activity, indenoisoquinolines were linked via their lactam side chains to provide polyamines end-capped with intercalating motifs. The resulting bisindenoisoquinolines were evaluated for cytotoxicity in the National Cancer Institute's human cancer cell screen and for Top1 inhibition. Preliminary findings suggested that the 2-3-2 and 3-3-3 linkers, referring to the number of carbons between nitrogen atoms, were optimal for both potent Top1 inhibition and cytotoxicity. Using optimized linkers, bisindenoisoquinolines were synthesized with nitro and methoxy substituents on the aromatic rings. The biological results for substituted compounds revealed a disagreement between the structure-activity relationships of monomeric indenoisoquinolines and bisindenoisoquinolines as Top1 inhibitors, but cytotoxicity was maintained for both series of compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16913702     DOI: 10.1021/jm060046o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.

Authors:  Trung Xuan Nguyen; Andrew Morrell; Martin Conda-Sheridan; Christophe Marchand; Keli Agama; Alun Bermingham; Alun Bermingam; Andrew G Stephen; Adel Chergui; Alena Naumova; Robert Fisher; Barry R O'Keefe; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-04-26       Impact factor: 7.446

2.  Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Authors:  Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

3.  Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.

Authors:  Yunlong Song; Zhiyu Shao; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

4.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

5.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

Review 6.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Authors:  Yves Pommier
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

7.  Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.

Authors:  Daniel E Beck; P V Narasimha Reddy; Wei Lv; Monica Abdelmalak; Gabrielle S Tender; Sophia Lopez; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-12       Impact factor: 7.446

8.  Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.

Authors:  Subhendu K Das; Arijit Ghosh; Srijita Paul Chowdhuri; Nyancy Halder; Ishita Rehman; Souvik Sengupta; Krushna Chandra Sahoo; Harapriya Rath; Benu Brata Das
Journal:  J Med Chem       Date:  2018-01-11       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.